Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
REVIEW
Soohyun Choe, Woori Kwak, Ehyun Kim, Sohyeon Shin, Miyoung Shin, Hyun Jung Koh, Hyunho Yoon
Most pancreatic cancers are pancreatic ductal adenocarcinomas. This is an extremely lethal disease with poor prognosis and almost no treatment choices. Considering the profound role of the pancreas in the human body, malfunction of this organ can significantly affect quality of life. Although multiple metabolic pathways are altered in cancer cells, certain metabolic gene signatures may be critical for immunotherapy. The reprogrammed metabolism of glucose, amino acids, and lipids can nourish the tumor microenvironment (TME)...
April 2, 2024: Frontiers in Bioscience (Landmark Edition)
#22
JOURNAL ARTICLE
Lijia Luo, Xiang Wang, Yu-Pei Liao, Xiao Xu, Chong Hyun Chang, Andre E Nel
The prevailing desmoplastic stroma and immunosuppressive microenvironment within pancreatic ductal adenocarcinoma (PDAC) pose substantial challenges to therapeutic intervention. Despite the potential of protein tyrosine kinase (PTK) inhibitors in mitigating the desmoplastic stromal response and enhancing the immune milieu, their efficacy is curtailed by suboptimal pharmacokinetics (PK) and insufficient tumor penetration. To surmount these hurdles, we have pioneered a novel strategy, employing lipid bilayer-coated mesoporous silica nanoparticles (termed "silicasomes") as a carrier for the delivery of Nintedanib...
February 2024: Nano Today
#23
JOURNAL ARTICLE
Yongji Sun, Sien Hu, Xiawei Li, Yulian Wu
Precise prognostication is vital for guiding treatment decisions in people diagnosed with pancreatic cancer. Existing models depend on predetermined variables, constraining their effectiveness. Our objective was to explore a novel machine learning approach to enhance a prognostic model for predicting pancreatic cancer-specific mortality and, subsequently, to assess its performance against Cox regression models. Datasets were retrospectively collected and analyzed for 9,752 patients diagnosed with pancreatic cancer and with surgery performed...
March 2024: Curēus
#24
Michael Teklehaimanot Abera, Yacob Sheiferawe Seman, Hidaya Yahya Mohammed, Fadil Nuredin Abrar, Admassu Melaku Mikru, Mahlet Kifle Mersha
Synchronous pancreatic neuroendocrine tumors and renal cell cancer are extremely rare. Von-Hipple-Landau syndrome is a major association. A 43-year-old male patient with left upper quadrant pain and significant weight loss was diagnosed with a synchronous pancreatic tail neuroendocrine tumor with solitary splenic metastasis and a clear-cell renal cell carcinoma of the left kidney. Sonography and a computed tomography scan of the abdomen showed a complex exophytic left renal mass and a necrotic lesion limited to the spleen...
July 2024: Radiology Case Reports
#25
JOURNAL ARTICLE
J Yu, G X Xiao, C Liu, L L Xie, X P Yang, L D Zheng
No abstract text is available yet for this article.
May 8, 2024: Zhonghua Bing Li Xue za Zhi Chinese Journal of Pathology
#26
JOURNAL ARTICLE
Chao-Hui Chang, Feng Liu, Stefania Militi, Svenja Hester, Reshma Nibhani, Siwei Deng, James Dunford, Aniko Rendek, Zahir Soonawalla, Roman Fischer, Udo Oppermann, Siim Pauklin
The lethality, chemoresistance and metastatic characteristics of cancers are associated with phenotypically plastic cancer stem cells (CSCs). How the non-cell autonomous signalling pathways and cell-autonomous transcriptional machinery orchestrate the stem cell-like characteristics of CSCs is still poorly understood. Here we use a quantitative proteomic approach for identifying secreted proteins of CSCs in pancreatic cancer. We uncover that the cell-autonomous E2F1/4-pRb/RBL2 axis balances non-cell-autonomous signalling in healthy ductal cells but becomes deregulated upon KRAS mutation...
April 27, 2024: Nature Communications
#27
JOURNAL ARTICLE
Meirion Raymant, Yuliana Astuti, Laura Alvaro-Espinosa, Daniel Green, Valeria Quaranta, Gaia Bellomo, Mark Glenn, Vatshala Chandran-Gorner, Daniel H Palmer, Christopher Halloran, Paula Ghaneh, Neil C Henderson, Jennifer P Morton, Manuel Valiente, Ainhoa Mielgo, Michael C Schmid
Pancreatic ductal adenocarcinoma (PDAC) is a highly metastatic disease for which better therapies are urgently needed. Fibroblasts and macrophages are heterogeneous cell populations able to enhance metastasis, but the role of a macrophage-fibroblast crosstalk in regulating their pro-metastatic functions remains poorly understood. Here we deconvolve how macrophages regulate metastasis-associated fibroblast (MAF) heterogeneity in the liver. We identify three functionally distinct MAF populations, among which the generation of pro-metastatic and immunoregulatory myofibroblastic-MAFs (myMAFs) critically depends on macrophages...
April 27, 2024: Nature Communications
#28
JOURNAL ARTICLE
Vivek Gupta, Vishakha Vashisht, Ashutosh Vashisht, Ashis K Mondal, Ahmet Alptekin, Harmanpreet Singh, Ravindra Kolhe
Copy number alterations (CNAs) are significant in tumor initiation and progression. Identifying these aberrations is crucial for targeted therapies and personalized cancer diagnostics. Next-generation sequencing (NGS) methods present advantages in scalability and cost-effectiveness, surpassing limitations associated with reference assemblies and probe capacities in traditional laboratory approaches. This retrospective study evaluated CNAs in 50 FFPE tumor samples (breast cancer, ovarian carcinoma, pancreatic cancer, melanoma, and prostate carcinoma) using Illumina's TruSight Oncology 500 (TSO500) and the Affymetrix Oncoscan Molecular Inversion Probe (OS-MIP) (ThermoFisher Scientific, Waltham, MA, USA)...
March 23, 2024: Genes
#29
JOURNAL ARTICLE
Valentina Giansante, Luca Di Angelo, Chiara Calabrese, Paolo De Sanctis, Paolo Regi, Filippo Maria Martelli, Gianmarco Stati, Rossano Lattanzio, Saverio Alberti, Emanuela Guerra, Roberta Di Pietro
Pancreatic cancer, most frequently as ductal adenocarcinoma (PDAC), is the third leading cause of cancer death. Clear-cell primary adenocarcinoma of the pancreas (CCCP) is a rare, aggressive, still poorly characterized subtype of PDAC. We report here a case of a 65-year-old male presenting with pancreatic neoplasia. A histochemical examination of the tumor showed large cells with clear and abundant intracytoplasmic vacuoles. The clear-cell foamy appearance was not related to the hyperproduction of mucins. Ultrastructural characterization with transmission electron microscopy revealed the massive presence of mitochondria in the clear-cell cytoplasm...
April 13, 2024: International Journal of Molecular Sciences
#30
REVIEW
Aayush Vishwanath, Shreyas Krishna, Albert P Manudhane, Phil A Hart, Somashekar G Krishna
There is growing recognition of early-onset gastrointestinal (GI) malignancies in young adults < 50 years of age. While much of the literature has emphasized colorectal cancer, these also include esophageal, gastric, liver, pancreatic, and biliary tract malignancies. Various factors, including lifestyle, hereditary, and environmental elements, have been proposed to explain the rising incidence of GI malignancies in the younger population. This review aims to provide an overview of the recent literature, including global trends and information regarding genetic and environmental risk factors...
April 18, 2024: Cancers
#31
REVIEW
Hala Muaddi, LaDonna Kearse, Susanne Warner
With an overall 5-year survival rate of 12%, pancreas ductal adenocarcinoma (PDAC) is an aggressive cancer that claims more than 50,000 patient lives each year in the United States alone. Even those few patients who undergo curative-intent resection with favorable pathology reports are likely to experience recurrence within the first two years after surgery and ultimately die from their cancer. We hypothesize that risk factors for these early recurrences can be identified with thorough preoperative staging, thus enabling proper patient selection for surgical resection and avoiding unnecessary harm...
April 15, 2024: Current Oncology
#32
REVIEW
Luca Filippi, Luca Urso, Laura Evangelista
Auger electrons (AEs) represent an intriguing topic in the field of radionuclide therapy. They are emitted by several radionuclides commonly used in nuclear medicine (indium-111, iodine-123, iodine-125), allowing for highly localized energy deposition and thus exerting a radiotoxic effect on specific cellular and sub-cellular targets. However, due to their short range in matter, AEs have had limited use in therapeutic applications so far. In recent years, the synthesis of various radiopharmaceuticals capable of binding to the enzyme poly(ADP-ribose) polymerase 1 has reignited interest in this type of therapy, laying the groundwork for a theranostic approach based on radionuclides emitting AEs...
March 31, 2024: Current Issues in Molecular Biology
#33
JOURNAL ARTICLE
Maite de Miguel-Palacio, Ana-María González-Castillo, María Martín-Ramos, Estela Membrilla-Fernández, Amalia Pelegrina-Manzano, María-José Pons-Fragero, Luis Grande-Posa, Juan-José Sancho-Insenser
INTRODUCTION: The current treatment for acute calculous cholecystitis (ACC) is early laparoscopic cholecystectomy, in association with appropriate empiric antibiotic therapy. In our country, the evolution of the prevalence of the germs involved and their resistance patterns have been scarcely described. The aim of the study was to analyze the bacterial etiology and the antibiotic resistance patterns in ACC. METHODS: We conducted a single-center, retrospective, observational study of consecutive patients diagnosed with ACC between 01/2012 and 09/2019...
April 23, 2024: Cirugia española
#34
REVIEW
Francesca Castagnoli, Justin Mencel, Derfel Ap Dafydd, Jessica Gough, Brent Drake, Naami Charlotte Mcaddy, Samuel Joseph Withey, Angela Mary Riddell, Dow-Mu Koh, Joshua David Shur
As the management of gastrointestinal malignancy has evolved, tumor response assessment has expanded from size-based assessments to those that include tumor enhancement, in addition to functional data such as those derived from PET and diffusion-weighted imaging. Accurate interpretation of tumor response therefore requires knowledge of imaging modalities used in gastrointestinal malignancy, anticancer therapies, and tumor biology. Targeted therapies such as immunotherapy pose additional considerations due to unique imaging response patterns and drug toxicity; as a consequence, immunotherapy response criteria have been developed...
May 2024: Radiographics: a Review Publication of the Radiological Society of North America, Inc
#35
RANDOMIZED CONTROLLED TRIAL
Sara Maher, Hesham A Elmeligy, Tarek Aboushousha, Noha Said Helal, Yousra Ossama, Mahmoud Rady, Ahmed Mohamed A Hassan, Manal Kamel
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with a highly immunosuppressive microenvironment. This single-blind, randomized study aimed to evaluate the synergistic immunomodulatory effects of synbiotics (probiotics and inulin prebiotics), as well as their impact on postoperative complications and outcomes, compared to the use of probiotics alone. Ninety patients diagnosed with PDAC were enrolled and randomly assigned into three groups: the placebo group, the probiotics group (receiving a mixture of ten strains of Lactobacillus, Bifidobacterium, and Streptococcus bacteria at a dose of 25 billion CFUs), and the synbiotics group (the same probiotics along with inulin prebiotics)...
April 25, 2024: Cancer Immunology, Immunotherapy: CII
#36
JOURNAL ARTICLE
M Lisa Zhang, Yuko Omori, Seung-Mo Hong, Noboru Ideno, Kenjiro Date, Dario M Rocha Castellanos, Stuti G Shroff, Giuseppe Zamboni, Raul S Gonzalez, Toru Furukawa, Carlos Fernandez-Del Castillo, Mari Mino-Kenudson
AIMS: Small invasive carcinomas arising in intraductal papillary mucinous neoplasms (IPMNs) of the pancreas can present as multiple, small foci. In such cases, there is no clear optimal measurement method for determining the invasive size for tumour staging and prognostication. METHODS: In all, 117 small invasive IPMNs (size of largest invasive component ≤2 cm) from seven institutions (2000-2016) were reviewed, and all individual foci of invasive carcinoma were measured...
April 25, 2024: Histopathology
#37
MULTICENTER STUDY
James Lucocq, Jake Hawkyard, Beate Haugk, Omar Mownah, Krishna Menon, Takaki Furukawa, Yosuke Inoue, Yuki Hirose, Naoki Sasahira, Michael Feretis, Anita Balakrishnan, Carlo Ceresa, Brian Davidson, Rupaly Pande, Bobby Dasari, Lulu Tanno, Dimitrios Karavias, Jack Helliwell, Alistair Young, Quentin Nunes, Tomas Urbonas, Michael Silva, Alex Gordon-Weeks, Jenifer Barrie, Dhanny Gomez, Stijn Van Laarhoven, Francis Robertson, Hossain Nawara, Joseph Doyle, Ricky Bhogal, Ewen Harrison, Marcus Roalso, Debora Ciprani, Somaiah Aroori, Bathiya Ratnayake, Jonathan Koea, Gabriele Capurso, Ruben Bellotti, Stefan Stättner, Tareq Alsaoudi, Neil Bhardwaj, Srujan Rajesh, Fraser Jeffery, Saxon Connor, Andrew Cameron, Nigel Jamieson, Amy Sheen, Anubhav Mittal, Jas Samra, Anthony Gill, Keith Roberts, Kjetil Søreide, Sanjay Pandanaboyana
BACKGROUND: The clinical impact of adjuvant chemotherapy after resection for adenocarcinoma arising from intraductal papillary mucinous neoplasia is unclear. The aim of this study was to identify factors related to receipt of adjuvant chemotherapy and its impact on recurrence and survival. METHODS: This was a multicentre retrospective study of patients undergoing pancreatic resection for adenocarcinoma arising from intraductal papillary mucinous neoplasia between January 2010 and December 2020 at 18 centres...
April 3, 2024: British Journal of Surgery
#38
JOURNAL ARTICLE
Xianlei Cai, Xueying Li, Chao Liang, Miaozun Zhang, Zhebin Dong, Weiming Yu
Metabolic factors play a critical role in the development of digestive system cancers (DSCs), and East Asia has the highest incidence of malignant tumors in the digestive system. We performed a two-sample Mendelian randomization analysis to explore the associations between 19 metabolism-related lifestyle and clinical risk factors and DSCs, including esophageal, gastric, colorectal, hepatocellular, biliary tract, and pancreatic cancer. The causal association was explored for all combinations of each risk factor and each DSC...
April 24, 2024: Scientific Reports
#39
JOURNAL ARTICLE
Yating Liu, Xinyu Li, Jie Yang, Shanshan Chen, Changyu Zhu, Yijun Shi, Shoutao Dang, Weitao Zhang, Wei Li
BACKGROUND: The major facilitator superfamily glucose transporters (GLUTs), encoded by solute carrier 2A (SLC2A) genes, mediate the transmembrane movement and uptake of glucose. To satisfy the improved energy demands, glycolysis flux is increased in cancers compared with healthy tissues. Multiple diseases, including cancer, have been associated with GLUTs. Nevertheless, not much research has been done on the functions of SLC2As in pan-cancer prognosis or their clinical treatment potential...
April 30, 2024: Heliyon
#40
JOURNAL ARTICLE
Anton Lahusen, Jierui Cai, Reinhold Schirmbeck, Anton Wellstein, Alexander Kleger, Thomas Seufferlein, Tim Eiseler, Yuan-Na Lin
Poor treatment responses of pancreatic ductal adenocarcinoma (PDAC) are in large part due to tumor heterogeneity and an immunosuppressive desmoplastic tumor stroma that impacts interactions with cells in the tumor microenvironment (TME). Thus, there is a pressing need for models to probe the contributions of cellular and noncellular crosstalk. Organoids are promising model systems with the potential to generate a plethora of data including phenotypic, transcriptomic and genomic characterization but still require improvements in culture conditions mimicking the TME...
April 23, 2024: Scientific Reports
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
